Sodium Sulfacetamide


Acella Pharmaceuticals, Llc
Human Prescription Drug
NDC 42192-129
Sodium Sulfacetamide is a human prescription drug labeled by 'Acella Pharmaceuticals, Llc'. National Drug Code (NDC) number for Sodium Sulfacetamide is 42192-129. This drug is available in dosage form of Liquid. The names of the active, medicinal ingredients in Sodium Sulfacetamide drug includes Sulfacetamide Sodium - 100 mg/mL . The currest status of Sodium Sulfacetamide drug is Active.

Drug Information:

Drug NDC: 42192-129
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Sodium Sulfacetamide
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Sodium Sulfacetamide
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Acella Pharmaceuticals, Llc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Liquid
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:SULFACETAMIDE SODIUM - 100 mg/mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED DRUG OTHER
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 04 Jan, 2011
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 23 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Acella Pharmaceuticals, LLC
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:1006107
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:4NRT660KJQ
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Sulfonamide Antibacterial [EPC]
Sulfonamides [CS]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
42192-129-16480 mL in 1 BOTTLE (42192-129-16)04 Jan, 2011N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Sodium sulfacetamide sodium sulfacetamide cocamidopropyl betaine edetate disodium pentaerythrityl tetrastearate caprylic/capric mono/diglycerides glyceryl monostearate methylparaben peg-60 almond glycerides polysorbate 60 water sodium laureth sulfate sodium thiosulfate sulfacetamide sodium sulfacetamide

Drug Interactions:

Drug interactions: sodium sulfacetamide 10% wash is incompatible with silver preparations.

Indications and Usage:

Indications: sodium sulfacetamide 10% wash is intended for topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff). it is also indicated for the treatment of secondary bacterial infections of the skin due to organisms susceptible to sulfonamides.

Warnings:

Warnings: sulfonamides are known to cause stevens-johnson syndrome in hypersensitivie individuals. stevens-johnson syndrome also has been reported following the use of sodium sulfacetamide topically. cases of drug induced systemic lupus erythematosus from topical sulfacetamide also have been reported. in one of these cases, there was a fatal outcome. keep out of the reach of children.

General Precautions:

General - nonsusceptible organisms, including fungi, may proliferate with the use of this preparation. hypersensitivity reactions may recur when a sulfonamide is readministered, irrespective of the route of administration, and cross hypersensitivity between different sulfonamides may occur. if sodium sulfacetamide 10% wash produces signs of hypersensitivity or other untoward reactions, discontinue use of the preparation. systemic absorption of topical sulfonamides is greater following application to large, infected, abraded, denuded, or severely burned areas. under these circumstances, potentially any of the adverse effects produced by the systemic administration of these agents could occur and appropriate observations and laboratory determinations should be performed.

Dosage and Administration:

Dosage and administration: seborrheic dermatitis including seborrhea sicca - wash affected areas twice daily (morning and evening), or as directed by your physician. avoid contact with eyes or mucous membranes. wet skin and liberally apply to areas to be cleansed, massage gently into skin working into a full lather, rinse thoroughly and pat dry. rinsing with plain water will remove any excess medication. repeat application as described for eight to ten days. if skin dryness occurs it may be controlled by rinsing cleanser off sooner or using less frequently. regular shampooing following sodium sulfacetamide 10% wash is not necessary, but the hair should be shampooed at least once a week. as the condition subsides, the interval between applications may be lengthened. applications once or twice weekly or every other week may prevent recurrence. should the condition recur after stopping therapy, the application of sodium sulfacetamide 10% wash should be reinstated as at the beginning of tr
eatment. secondary cutaneuos bacterial infections - wet skin and liberally apply to areas to be cleansed, massage gently into skin working into a full lather, rinse thoroughly and pat dry. rinsing with plain water will remove any excess medication. repeat application as described for eight to ten days. if skin dryness occurs it may be controlled by rinsing cleanser off sooner or using less often.

Contraindications:

Contraindications: sodium sulfacetamide 10% wash is contraindicated for use by patients having known hypersensitivity to sulfonamides or any other component of this product.

Adverse Reactions:

Adverse reactions: reports of irritation and hypersensitivity to sodium sulfacetamide are uncommon. the following adverse reactions, reported after administration of sterile ophthalmic sodium sulfacetamide, are noteworthy: instances of stevens-johnson syndrome and instances of local hypersensitivity which progressed to a syndrome resembling systemic lupus erythematosus; in one case a fatal outcome was reported. (see warnings .)

Drug Interactions:

Drug interactions: sodium sulfacetamide 10% wash is incompatible with silver preparations.

Use in Pregnancy:

Pregnancy: category c. animal reproduction studies have not been conducted with sodium sulfacetamide 10% wash. it is not known whether sodium sulfacetamide 10% wash can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. sodium sulfacetamide 10% wash should be given to a pregnant woman only if clearly needed or when potential benefits outweigh potential hazards to the fetus.

Pediatric Use:

Pediatric use: safety and effectiveness in children under the age of 12 have not been established.

Overdosage:

Overdosage: the oral ld 50 of sulfacetamide in mice is 16.5 g/kg. in the event of overdosage, emergency treatment should be started immediately. manifestations: overdosage may cause nausea and vomiting. large oral overdosage may cause hematuria, crystalluria and renal shutdown due to the precipitation of sulfa crystals in the renal tubules and the urinary tract. for treatment, contact your local poison control center.

Description:

Description: sodium sulfacetamide is c 8 h 9 n 2 nao 3 s·h 2 o with molecular weight of 254.24. chemically, it is acetamide n-[(4-aminophenyl) sulfonyl]-acetamide, monosodium salt, monohydrate. the structural formula is: each gram of sodium sulfacetamide 10% wash contains 100 mg of sodium sulfacetamide, usp in a formulation containing cocamidopropyl betaine, disodium edta,peg-150 pentaerythrityl tetrastearate and peg 6 caprylic/capric glycerides, glyceryl monostearate, methyl paraben, peg-60 almond triglyceride, polysorbate 60, purified water, sodium lauryl sulfate and sodium thiosulfate. sodium sulfacetamide is an odorless, white, crystalline powder with a bitter taste. it is freely soluble in water, sparingly soluble in alcohol, while practically insoluble in benzene, in chloroform and in ether. structure

Clinical Pharmacology:

Clinical pharmacology: sodium sulfacetamide exerts a bacteriostatic effect against sulfonamide sensitive gram-positive and gram-negative microorganisms commonly isolated from secondary cutaneous pyogenic infections. it acts by restricting the synthesis of folic acid required by bacteria for growth, by its competition with para-aminobenzoic acid. there is no clinical data available on the degree and rate of systemic absorption of sodium sulfacetamide 10% wash when applied to the skin or scalp. however, significant absorption of sodium sulfacetamide through the skin has been reported. the following in vitro data is available but the clinical significance is not known. organisms which show susceptibility to sodium sulfacetamide are: streptococci, staphylococci, e. coli, klebsiella pneumonia, pseudomonas pyocyanea, salmonella species, proteus vulgaris, nocardia and actinomyces .

Carcinogenesis and Mutagenesis and Impairment of Fertility:

Carcinogenesis, mutagenesis and impairment of fertility - long-term studies in animals have not been performed to evaluate carcinogenic potential. studies on reproduction and fertility also have not been performed. chromosomal nondisjunction in the yeast, saccharomyces cerevisiae, following application of sodium sulfacetamide has been reported. the significance of this finding to the topical use of sodium sulfacetamide in the human is not known.

How Supplied:

How supplied: sodium sulfacetamide 10% wash is available in 16 fluid ounce bottles, ndc 42192-129-16.

Information for Patients:

Information for patients - patients should discontinue use of sodium sulfacetamide 10% wash if the condition worsens, or is a rash develops in the area being treated or elsewhere. sodium sulfacetamide 10% wash also should be discontinued promptly and the physician notified if any arthritis, fever or sores in the mouth develop.

Package Label Principal Display Panel:

Package label - 10% wash ndc 42192-129-16 sodium sulfacetamide 10% wash rx only for external use only 16 fl. oz. (480 ml) acella pharmaceuticals, llc container


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.